Paris (France), San Francisco (USA) – November 18th, 2025 – Lauxera Capital Partners, a leading private equity firm focused on innovative and fast-growing Healthtech companies, is pleased to announce the appointment of Dr. Oern Stuge as Senior Advisor. Dr. Stuge brings decades of executive and board-level experience across the global healthcare industry, strengthening Lauxera’s mission to support and scale transformative health innovation.
With a distinguished career spanning leadership roles in both multinational corporations and emerging medtech ventures, Dr. Stuge has developed deep expertise in operational excellence, global market expansion, and corporate governance. He served as a member of the Executive Committee at Medtronic, one of the world’s largest medical technology companies, where he held various senior positions, including President of Europe, Middle East, and Africa. More recently, Dr. Stuge has been an active investor, advisor, and chairman to several healthcare companies worldwide.
“We are thrilled to welcome Oern to the Lauxera team,” said Samuel Levy, Co-founding Partner at Lauxera Capital Partners. “His global perspective, hands-on experience in scaling healthcare businesses, and passion for innovation will be invaluable as we continue to back European Healthtech champions. We have already had the privilege of working successfully together on OrganOx, which achieved an outstanding outcome with its sale to Terumo in August 2025 for approximately $1.5bn — a testament to Oern’s strategic insight and deep operational acumen.”
Dr. Stuge added: “I am excited to join Lauxera at a time when European Healthtech is demonstrating such strong growth potential. Lauxera’s entrepreneurial and partnership-driven approach aligns perfectly with my belief in empowering great teams to deliver impactful solutions to patients worldwide.”
As Senior Advisor, Dr. Stuge will support Lauxera’s investment team in identifying and nurturing high growth opportunities, while mentoring portfolio company leaders to accelerate their international expansion and operational maturity.
